Dr RR Baliga's "Got Knowledge Doc" Podkast

Dr RR Baliga's "Got Knowledge Doc" Podkast

By Dr RR Baliga, MD, MBAScienceEducationNatural Sciences
Download on the App Store

Dr RR Baliga's "Got Knowledge Doc" Podkast episodes

  • Can AI think like a physician? 🧠🤖

    Can AI think like a physician? 🧠🤖

    A landmark Science 2026 study shows LLMs outperform physicians in structured diagnostic reasoning across NEJM cases and real-world emergency scenarios. 📊

    Accuracy gains were striking—especially in early triage where uncertainty is highest. Yet, the story is not replacement, but partnership. 🤝

    The real challenge now: translating benchmark brilliance into safe, equitable, real-world care. ⚖️

    AI is no longer a tool—it's becoming a colleague. The question is: how do we train, trust, and integrate it? 🚀

    9 min
  • TB: Point-of-Care. Precision. Progress. 📍🧠📈

    A quiet revolution in tuberculosis diagnostics is here. 🧪🌍

    This NEJM study shows that MiniDock MTB, a rapid swab-based molecular test, delivers Xpert-level accuracy with minimal training and no adverse events—all in a near–point-of-care format. ⏱️🧠

    Key insights: 🔹 Sensitivity: 85.7% (sputum), 79.6% (tongue) 🔹 Specificity: >97–99% 🔹 Strong performance vs smear microscopy (+24% sensitivity) 🔹 Usability score: 75—ready for real-world deployment

    The implications are profound: 👉 Noninvasive testing for patients unable to produce sputum 👉 Decentralized diagnostics in resource-limited settings 👉 A realistic path to closing the global TB detection gap

    From central labs to community clinics—this is how access scales. 🚀

    📖 Yerlikaya et al., NEJM 2026

    #Tuberculosis #GlobalHealth #Diagnostics #PointOfCare #PublicHealth #InfectiousDiseases #PrecisionMedicine #MedicalInnovation #HealthEquity #TBElimination

    5 min
  • Fueling Immunity: When Eating Becomes Therapy 🍽️💊🛡️

    A meal may be more than nutrition—it may be immunotherapy. 🍽️⚡

    In a striking Nature study, T cells sampled just 6 hours after feeding showed enhanced metabolic fitness, cytokine production, and persistence compared to the fasted state. 🧠🔥

    Mechanistically, chylomicron-derived lipids → LDLR → mTORC1 → protein translation, fueling durable immune function.

    Even more compelling: postprandial CAR-T cells demonstrated superior cytotoxicity.

    Clinical implication? Timing may matter—before vaccines, before cell therapy, before immune engagement. ⏱️

    Feed. Fuel. Fight. 🛡️✨

    6 min
  • CKD. Control BP. Cardioprotection. 🧬❤️📉

    BP Lowering in CKD: Consistent. Comprehensive. Compelling. 📉🫀

    A landmark individual-participant meta-analysis (285K+ patients) shows that every 5 mm Hg reduction in systolic BP reduces major cardiovascular events by ~10%—across all CKD stages.

    Key insight: the benefit holds even at lower BP levels and across drug classes. ⚖️ But in CKD + diabetes, the effect attenuates—reminding us that biology resists simplicity. 🧠

    The message is clear: BP control remains one of the most powerful, scalable tools in CKD care.

    Precision is next. Implementation is everything. 🚀

    7 min
  • Great Doctors Series: Charaka-Balance. Body. Beginnings. 🌿🧠📜

    🌿 Balance. Body. Beginnings.

    Long before modern medicine spoke of personalization and prevention, Charaka articulated a remarkably sophisticated vision of health—rooted in balance, biology, and behavior.

    From the Charaka Samhita to the concept of doshas (vata, pitta, kapha), his work reflects an early systems-based approach that continues to echo in today's precision and lifestyle medicine.

    This infographic from Dr RR Baliga's Podkast for the Kurious Doc 🎙️🧠 explores how ancient insights still inform modern thinking

    ✨ Where curiosity meets clarity #Ayurveda #MedicalHistory #HolisticHealth #PrecisionMedicine #LifestyleMedicine

    5 min
  • Persistant Atrial Fibrillation: Pulse Field Ablation Dominates

    ⚡🫀 Shock. Silence. Success — A landmark New England Journal of Medicine trial redefines first-line therapy in persistent AF.

    In AVANT GUARD, pulsed field ablation (PFA) outperformed antiarrhythmic drugs: 📊 Success: 56% vs 30% 📉 HR: 0.46 (P 💓 Lower arrhythmia burden (−6.5%)

    Safety remained comparable, with primary events at 5.1%.

    A compelling case for early, energy-based rhythm control—precision over pharmacology.

    #Cardiology #Electrophysiology #AtrialFibrillation #NEJM #Innovation

    4 min
  • Cancer of the Heart: Pressure. Chromatin. Control. ❤️‍🔥🧬⚙️

    A fascinating Science (2026) study reveals why the heart is remarkably resistant to cancer.

    Mechanical load—through contraction and pressure—suppresses tumor proliferation via epigenetic remodeling.

    Unloading the heart doubled cancer cell proliferation, while load reduced histone methylation and chromatin compaction through Nesprin-2–mediated mechanotransduction.

    A striking paradigm: the beating heart is not just a pump—but a biomechanical tumor suppressor. 🫀⚙️🧬 @ICOSociety

    4 min
  • Triple Pill. Tighter Pressure. Fewer Strokes. 🧠💊📉

    A simple idea, executed elegantly.

    In the NEJM TRIDENT trial, a single low-dose triple antihypertensive pill reduced recurrent stroke after intracerebral hemorrhage (HR 0.61) and improved BP control (50% vs 26%).

    Yet, only half reached target—reminding us that pills alone don't solve therapeutic inertia.

    The message is clear: simplify treatment, intensify targets, and build systems that ensure control.

    One pill helps. Systems save lives. 💊📉🧠

    6 min
  • Epigenetics. Synergy. Survival. 🧬💊📈 in in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma

    A pivotal JAMA randomized trial introduces an epigenetic twist to frontline therapy in high-risk DLBCL. Adding tucidinostat (HDAC inhibitor) to R-CHOP improved event-free survival (HR 0.72, P=0.02) and increased complete response rates (73% vs 62%) in MYC/BCL2 double-expressor lymphoma. Toxicity was higher but manageable.

    A quiet but meaningful shift—targeting biology, not just burden.

    #DLBCL #Lymphoma #Oncology #PrecisionMedicine #JAMA #ClinicalTrials

    5 min
  • 🎯⏳🏆: Rethinking Antibiotics of UTI Therapy

    A pragmatic Lancet RCT (SCOUT) reshapes UTI management. In 768 women, nitrofurantoin achieved the highest clinical resolution at day 7 (74%) vs single-dose fosfomycin (59%), with a significant 15.5% absolute difference. Pivmecillinam and two-dose fosfomycin performed intermediately. Adverse events were mild across groups.

    The message is clear: convenience may cost efficacy. Short-course regimens—especially nitrofurantoin—should be preferred over single-dose fosfomycin. A timely reminder that in antimicrobial stewardship, simplicity must not trump success

    5 min

About Dr RR Baliga's "Got Knowledge Doc" Podkast

From the publisher's feed

"Got Knowledge Doc" Podkast with Dr. RR Baliga

More shows like Dr RR Baliga's "Got Knowledge Doc" Podkast

This Week in Cardiology by Medscape

This Week in Cardiology

893 Listeners

The Curbsiders Internal Medicine Podcast by The Curbsiders Internal Medicine Podcast

The Curbsiders Internal Medicine Podcast

3,351 Listeners

The Mel Robbins Podcast by Mel Robbins

The Mel Robbins Podcast

19,270 Listeners